[
  {
    "ts": null,
    "headline": "Does Incyte's Expanding Drug Pipeline Signal an Opportunity Following a 46.8% Price Surge?",
    "summary": "Thinking about whether Incyte might be worth more than its current price tag? You are not alone, as many investors are asking the same question right now. The stock has surged 46.8% year-to-date, climbing 42.3% over the past 12 months, despite taking a minor 2.0% dip in the last week. Recent headlines have centered on Incyte’s expanding drug pipeline and positive updates around new FDA approvals, fueling optimism and catching the attention of analysts and shareholders. These developments are...",
    "url": "https://finnhub.io/api/news?id=9dc4bf38293bbdf91266a32eabff499e6d8259c7ebfc9cba1c7d9476f1d4b19a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763874525,
      "headline": "Does Incyte's Expanding Drug Pipeline Signal an Opportunity Following a 46.8% Price Surge?",
      "id": 137587070,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Thinking about whether Incyte might be worth more than its current price tag? You are not alone, as many investors are asking the same question right now. The stock has surged 46.8% year-to-date, climbing 42.3% over the past 12 months, despite taking a minor 2.0% dip in the last week. Recent headlines have centered on Incyte’s expanding drug pipeline and positive updates around new FDA approvals, fueling optimism and catching the attention of analysts and shareholders. These developments are...",
      "url": "https://finnhub.io/api/news?id=9dc4bf38293bbdf91266a32eabff499e6d8259c7ebfc9cba1c7d9476f1d4b19a"
    }
  }
]